Rank 92 • MedTech & Devices
Biolinq
Develops an intradermal continuous glucose monitoring platform using a microneedle array for metabolic health tracking.
Visit website- Signal Score
- 82.4
- Total raised
- $175M
- Stage
- Series B
- Founded
- 2012
- Headquarters
- San Diego, USA
- Region
- North America
Their signal
Positioned as a next-generation contender in metabolic monitoring, its patch targets the intradermal space rather than subcutaneous tissue, offering a less invasive alternative to market incumbents.
Signal Score 82.4editorial estimate, see how it is built
Total raised, quality of investors and recency of the last round.
Revenue trajectory, customer count, hiring and market pull.
Peer-reviewed evidence, FDA/CE clearances and live health-system deployments.
Founder track record, clinical depth on the bench and technical leadership.
Search presence, press coverage, founder and brand reach, and how often the company shows up where buyers look.
Also in MedTech & Devices
Figures are subjective research desk estimates compiled from public sources and refreshed daily, published as editorial commentary. Company marks are shown for identification only and imply no endorsement or affiliation. Want a correction, an update or removal? and see our corrections and removals policy.